Altogether, these findings suggest that STAB1 expression may be associated with myeloid mechanisms that impair T cells from reaching the tumour site, and thus, limiting the efficacy of ICI therapies.71 Thus, we investigated the correlation of STAB1 expression across all cancer patients of the PANCAN study with recently described T-cell dysfunction and activation signatures.69 Strikingly, STAB1 significantly correlated with signatures that predict CTL dysfunction, but negatively with those associated with CTL activation (Fig. 3d). Here, STAB1 is linked to neoplasm.